Evaluation of the Long-term Safety and Effectiveness of Suzetrigine (SUZ) in Participants With Painful Diabetic Peripheral Neuropathy (DPN)

← catalyst calendar

NCT06696443 · readout in 159 d

Sponsored by Vertex Pharmaceuticals Incorporated (industry) · VRTX — their whole pipeline →.

Phase

Phase 3

Status

Active, not recruiting

Study type

Interventional

Design

Na · None · Treatment

Enrollment

455actual

Sites

Country

United States

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2024-12-18

actual

When the study began enrolling

Primary completion

2027-01-25

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

2027-01-25

estimated

The whole study's end, after follow-up

First posted

2024-11-20

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-05-18

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

Diabetic Peripheral Neuropathic Pain

Intervention

Drug: Suzetrigine — also filed as VX-548, SUZ

Primary outcome

what the primary-completion date above is the date OF

Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

measured From Baseline up to Week 54

Publications

PMID 41384808 — linked by the registry

Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.

Permalink · VRTX's whole pipeline · Catalyst calendar · Every registered study · What changed